Is there a Crysvita (burosumab) biosimilar available yet?
Crysvita is the brand name for burosumab, a biologic (a monoclonal antibody). Whether a “Crysvita biosimilar” is already available depends on the country and whether a biosimilar has received approval and been launched by a manufacturer. With the information provided here, I can’t confirm any specific approved Crysvita biosimilar product, its approval status, or launch dates.
What would count as a “Crysvita biosimilar” (and how is it regulated)?
In practice, a “Crysvita biosimilar” would be a biosimilar to burosumab, meaning it is approved by a medicines regulator (for example, the FDA in the US or the EMA in Europe) as highly similar to the reference product, with no clinically meaningful differences in terms of safety, purity, and potency. Approval typically relies on a stepwise package including analytical similarity, nonclinical data, and clinical data in relevant indications.
Which indications is burosumab (Crysvita) used for?
Crysvita is used for conditions related to impaired phosphate regulation. If you tell me your country (or whether you mean US/EU/UK/Canada/etc.), I can focus on the exact indications and what a biosimilar approval would need to cover there.
How do you check if a biosimilar exists in your country?
If you share your location, you can check:
- The national regulator’s “biosimilar” or “biologics” approvals page for burosumab
- The product registry entry for burosumab (to see reference vs. biosimilar naming)
- Major pharmacy chains or hospital formularies (for availability/brand names)
What patients ask when a biosimilar becomes available
People typically look for:
- Whether doctors must switch automatically or can use either product
- Differences in injection device, dosing schedule, and coverage by insurance/health systems
- Substitution rules (automatic vs. physician-led switching), which vary by country
Tell me what you need so I can answer precisely
To give a concrete answer (product name(s), approval/launch status, and likely indications), tell me:
1) Your country/region (US, EU, UK, Canada, etc.)
2) Whether you’re looking for a specific biosimilar candidate name or just “is one available?”
3) If this is for general information or for switching a current prescription